On Feb. 21 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration said a guidance is now available on industry implementation of Physician Labeling Rule content and format requirements in labeling for human drug and biological products. FDA said the guidance will assist applicants in developing labeling for new products, revising existing labeling, and implementing the physician labeling requirements. The Physician Labeling Rule, published in 2006, addresses prescription drug labeling that is used by prescribers and other health care practitioners. Comments on the guidance may be submitted at any time, FDA said. The guidance is available here.
On Feb. 20 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
During the week of Feb. 11-17, the Food and Drug Administration modified the following existing Import Alerts (not otherwise listed on the FDA's new and revised import alerts page) on the detention without physical examination and/or surveillance of:
The Food and Drug Administration sent a warning letter to Belgian device manufacturer Medsys, alleging several violations of FDA regulations including Medical Device Reporting. FDA said it will deny premarket approval applications for Class III devices related to the violations, and will not grant requests for certificates to foreign governments, until the violations have been corrected.
The Food and Drug Administration said a draft guidance on distinguishing device recalls from product enhancements is now available. The guidance would clarify when a change to a device meets the definition of a recall, and whether FDA should be notified. Device improvements do not necessarily mean old versions of a device need to be recalled, FDA said, but when the new version of a device corrects an identified defect or failure the public should be notified without delay. Comments on the draft guidance are due by May 23.
On Feb. 19 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
In arguing that the Food and Drug Administration’s implementation of the Food Safety Modernization Act has been too slow, “plaintiffs fail to appreciate the complexity of the tasks at hand and the real, concrete, and substantial progress the agency has made to date,” said the FDA in its reply to the Center for Food Safety’s Jan. 11 motion to compel issuance of several long-overdue FSMA regulations. The non-profit wants the Northern California District Court to mandate a timetable for FDA to issue FSMA regulations, including third-party auditing and the Foreign Supplier Verification Program.
The Food and Drug Administration is asking for comments by May 21 on a request to change the standard of identity for milk and 17 other dairy products to allow use of artificial sweeteners in flavorings used in milk. The petition, filed by the International Dairy Foods Association and the National Milk Producers Federation, seeks to amend several standards of identity in 21 CFR 131 to allow use of “any safe and suitable sweetener” in optional characterizing flavoring ingredients used in milk. The provisions currently allow use of a “nutritive sweetener.” The amendments would allow use of aspartame in flavored milk and milk products, promoting more healthful eating practices and reducing childhood obesity, the petitioners said.
On Feb. 14 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of: